Taking decisions on expenditure for high-cost drugs at the regional level: a model for evaluating the overall impact of Trastuzumab in the Veneto Region of Italy

J Eval Clin Pract. 2011 Apr;17(2):298-303. doi: 10.1111/j.1365-2753.2010.01440.x. Epub 2010 Sep 28.

Abstract

Introduction: Cost-effectiveness analysis provides a ratio that indicates the value created per unit of money by a given therapy but says nothing about the total expected costs or net health and social impact of this therapy in a particular population of interest.

Objective: The main objective of this study is to define a methodology to calculate the effects of interventions from a local perspective. This will help determine parameters that provide information about resource planning and management to local decision makers.

Methods: The described methodology calculates four indicators using local demographic and epidemiological data and a Markovian decision tree approach.

Results: The method was applied to evaluate the economic, health and social impact of introducing a new cancer drug, Trastuzumab, for the early treatment of breast cancer in the Veneto Region of Italy.

Discussion: The indicators described in this study allow public policy makers to clearly understand the benefits and costs of a particular health intervention in a local population and to compare it with other strategies.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / economics*
  • Child
  • Child, Preschool
  • Cost-Benefit Analysis / methods
  • Decision Making*
  • Drug Costs*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Italy
  • Markov Chains
  • Middle Aged
  • Models, Theoretical
  • Resource Allocation
  • Trastuzumab
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Trastuzumab